Biomarkers in Blood and Tumor Tissue Samples From Patients With Wilms Tumor
NCT ID: NCT01314391
Last Updated: 2016-05-18
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
20 participants
OBSERVATIONAL
2011-08-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
PURPOSE: This research study is studying biomarkers in blood and tumor tissue samples from patients with Wilms tumor.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Studying Biomarkers in Samples From Younger Patients With Wilms Tumor
NCT01576198
Studying Biomarkers in Samples From Younger Patients With Wilms Tumor
NCT01542333
Biomarkers in Samples From Younger Patients With Wilms Tumor
NCT01493817
Biomarkers in Tumor Tissue Samples From Young Patients With Very Low Risk Wilms Tumors
NCT01004783
Biomarkers in Urine Samples From Patients With Wilms Tumor
NCT01550393
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
* To determine whether Wilms Tumor (WT) patients without WT1-associated congenital anomalies or syndromes, but with end-stage renal disease (ESRD) unrelated to progressive bilateral tumors, carry germline WT1 mutations.
* To determine whether non-syndromic WT1 germline mutation carriers have a substantially higher incidence of ESRD than do WT patients who do not harbor WT1 mutations.
OUTLINE: Archived blood and tumor tissue specimens (or DNA isolated from these samples) are analyzed for WT1 mutations by gene sequencing and PCR.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
CASE_CONTROL
RETROSPECTIVE
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
mutation analysis
polymerase chain reaction
laboratory biomarker analysis
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Diagnosis of Wilms Tumor (WT)
* Patients who participated in the NWTS-5 protocol
* Non-syndromic patients who developed end-stage renal disease (ESRD) during 5-10 years for reasons other than progressive bilateral WT
* Matched control patients who had not developed ESRD by the time (since WT onset) of ESRD diagnosis
* Blood and tumor tissue samples available
PATIENT CHARACTERISTICS:
* Not specified
PRIOR CONCURRENT THERAPY:
* Not specified
15 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Children's Oncology Group
NETWORK
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Vicki Huff, PhD
Role: PRINCIPAL_INVESTIGATOR
M.D. Anderson Cancer Center
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
COG-AREN11B1
Identifier Type: OTHER
Identifier Source: secondary_id
NCI-2011-02850
Identifier Type: REGISTRY
Identifier Source: secondary_id
AREN11B1
Identifier Type: OTHER
Identifier Source: secondary_id
AREN11B1
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.